Professor of tumors: a new drug for the prevention of breast cancer by the success of 65%

Dr. Hamdi Abdel-Azim, a professor of oncology, the results of a recent study presented results for the first time in the annual conference of the American Cancer Society in Chicago, and showed the possibility of prevention of diseases, breast cancer success rate of 65%, using the drug has been used before for the treatment of patients.
The Abdel-Azim said the study represents the second generation of studies on this topic, was conducted under the auspices of the National Cancer Institute of Canada with other groups in conjunction with Harvard University and published the first time in June 2011, and included 4560 patients from the women most at risk of developing breast cancer, and who been identified over the age of 60 years, and have a family history of breast cancer for more than two people.
He pointed out that the study began in February 2004 and did not know where the doctor or patient drug used in treatment.
Abdul Azim said that the results of the study confirmed the success of this drug in the prevention of spread of the disease by more than 65%, confirming that there is still a chance by 35% to infection due to other factors, pointing out that the side effect is the only cure is new is the increased risk of osteoporosis, which can be treated by drugs.
The Abdel-Azim that the first generation of studies was based on another property he was working through antagonism action of the hormone «estrogen», and the success rate in preventing the formation of estrogen about 34%, but the one most important side effects is to increase the incidence of cervical cancer, indicating that that figure was a slight but definite, making 4% of women who have a willingness to develop breast cancer only to file a treatment it because of side effects.
It is due to announce Dr. Abdul Azim This results in Egypt through the Egyptian Cancer Society.
He pointed out that the coming period will see the detailed programs for the treatment of breast cancer for each individual case, according to the well-studied, not the programs prepared in advance for all patients, given the diversity of drugs involved and the realization that breast cancer is in fact more than one disease, each disease has its characteristics and their own constituencies and method of treatment